PRISM EHR-based model identifies adults at high risk for pancreatic ductal adenocarcinoma in real-world setting
Your Medical Records Might Flag Pancreatic Cancer Years Before Symptoms Appear
In a prospective multicenter cohort study of 6,282,123 adults, an EHR-based risk model identified individuals at high risk for pancreatic du…
An AI tool using routine health records can flag pancreatic cancer risk up to 3.5 years before symptoms appear in adults 40 and older.
Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
AI Now Reads Tumor Slides Like a Radiologist — and Shows Its Work
This review/commentary outlines a Virtual Spectral Decomposition (VSD) methodological framework for analyzing digital pathology and imaging …
A new AI system reads cancer slides like a doctor and explains exactly which biological features drove each diagnosis.
Gemcitabine exposure associated with higher TP53 and PI3K pathway alterations in pancreatic ductal adenocarcinoma tumors
AI Finds Hidden Keys to Pancreatic Cancer Survival
This cohort study analyzed 184 pancreatic ductal adenocarcinoma tumors to assess the association between gemcitabine exposure and molecular …
Age and gemcitabine exposure drive distinct genetic patterns in pancreatic cancer, directly influencing survival rates for patients with key…
Review of Virtual Spectral Decomposition for pancreatic cancer detection on CT scans
Virtual spectral decomposition shows promise for detecting pancreatic cancer field effects on standard CT scans
This review and synthesis evaluates a computational imaging method, Virtual Spectral Decomposition (VSD), applied to standard portal-venous …
A new image analysis method can spot subtle changes in the pancreas on standard CT scans, helping to find early signs of cancer before a tum…
Review of CAR-T cell therapy for pancreatic ductal adenocarcinoma reports no specific outcomes or safety data
First CAR-T for Pancreatic Cancer Approved
This narrative review addresses the application of CAR-T cell therapy for pancreatic ductal adenocarcinoma.
For the first time, a new drug approved for pancreatic cancer uses immune cells to attack solid tumors instead of just blood cancers.
Setidegrasib shows antitumor activity in advanced NSCLC and pancreatic cancer with p.G12D variants
A Drug That Shreds a Famous Cancer Target
This Phase 1 study evaluated setidegrasib in 203 patients with previously treated advanced solid tumors harboring p.G12D variants.
A first-of-its-kind drug called setidegrasib shrank lung and pancreatic tumors in patients with a cancer mutation that has frustrated drugma…
Tumor-associated neutrophils regulate PDAC progression via TGF-β and CXCR2 pathways
Can stopping white blood cells help stop pancreatic cancer from growing?
This systematic review examined tumor-associated neutrophils (TANs) in patients with pancreatic ductal adenocarcinoma (PDAC).
White blood cells that shield pancreatic cancer from treatment can be reprogrammed to fight the disease instead of fueling its growth.
Epigenomic ctDNA profiling identifies PDAC subtypes and improves prognostication over tissue-based methods in metastatic disease
Can a blood test predict pancreatic cancer subtypes better than tissue samples?
This multi-institutional cohort study evaluated epigenomic profiling of circulating tumor DNA (ctDNA) for subtyping pancreatic ductal adenoc…
A new blood test matches tissue samples and predicts patient outcomes better for metastatic pancreatic cancer, offering a hopeful step towar…
New-onset diabetes in adults over 50 associated with higher pancreatic cancer risk within 3 years
Could new diabetes after age 50 signal hidden pancreatic cancer?
A systematic review found individuals around 50 years and over with new-onset diabetes have a higher risk for pancreatic ductal adenocarcino…
New diabetes after age 50 might signal hidden pancreatic cancer, as patients face a higher risk of diagnosis within three years compared to …
Research across Cancer
Related studies from across the Cancer family.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis
A rare cancer spread inside the esophagus wall needs careful treatment plans for older adults
This case report and literature review examines a 77-year-old male with adenocarcinoma of the esophagogastric junction and esophageal intram…
A doctor reviewed a rare case where cancer spread inside the esophagus wall. This condition often means the disease is already in the body. …
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma
One Type of Cervical Cancer Is Far More Dangerous Than Others
This systematic review and meta-analysis synthesized comparative studies on HPV-independent and HPV-associated cervical adenocarcinoma. It f…
A large new analysis reveals that women with HPV-negative cervical adenocarcinoma face nearly three times the risk of death compared to thos…
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
TaTME shows lower conversion rates with similar short-term safety compared to LapTME for low rectal cancer
New surgical approach for rectal cancer cuts conversion rate
This randomized trial compared transanal total mesorectal excision with laparoscopic total mesorectal excision for patients with low rectal …
A new surgical technique for rectal cancer reduces the need to switch to open surgery, with similar complication rates.
Meta-analysis shows percutaneous irreversible electroporation plus immunotherapy improves outcomes in locally advanced pancreatic cancer
Adding immunotherapy to ablation therapy extends life for pancreatic cancer patients
This systematic review and meta-analysis evaluated percutaneous irreversible electroporation combined with immunotherapy versus irreversible…
Adding immune therapy to ablation therapy helps patients live longer with locally advanced pancreatic cancer without causing more side effec…
Retrospective analysis finds sarcopenia associated with shorter disease-free survival in pancreatic neuroendocrine tumor patients
Low muscle mass linked to shorter disease-free survival in pancreatic tumor patients
This retrospective cohort study included 86 patients who underwent curative-intent resection for pancreatic neuroendocrine tumors.
Low muscle mass before surgery was linked to shorter disease-free survival in patients with pancreatic neuroendocrine tumors, though this li…
H. pylori prevalence 34.3% in French Guiana; gastric adenocarcinoma found in 1.65%
One Third of Stomach Tests Show Hidden Bacteria Risk
A retrospective cohort study of 545 patients with H.
A new look at stomach biopsies shows one in three patients carry a hidden bacteria that can lead to serious disease.
Adjuvant chemotherapy improves overall survival in resectable stage I-III duodenal adenocarcinoma patients
After Surgery, This Extra Step May Extend Survival in Rare Cancer
This retrospective cohort study evaluated 98 patients with resectable stage I-III duodenal adenocarcinoma at two Chinese institutions.
After surgery for duodenal cancer, adding chemotherapy may nearly double survival time, but larger trials are still needed.
In a prospective cohort, periampullary tumor surgery affected quality of life and survival metrics
Life After Major Cancer Surgery Isn’t What We Thought
This prospective cohort study evaluated 111 patients undergoing pancreaticoduodenectomy for periampullary tumors at a University Medical Cen…
Imagine waking up after major cancer surgery.
Questions about Pancreatic Ductal Adenocarcinoma
What is the prevalence of CLDN18.2 expression in patients with pancreatic ductal adenocarcinoma?
About 52% of PDAC patients express CLDN18.2, but prevalence varies by testing method; 27% meet clinical trial positivity criteria.
Full answer →Can AI models improve diagnostic accuracy for pancreatic ductal adenocarcinoma compared to conventional methods?
Yes, AI models improve diagnostic accuracy for pancreatic ductal adenocarcinoma compared to conventional methods, with radiomics and machine learning showing high sensitivity and specificity.
Full answer →